OKYO Pharma (OKYO) Competitors $1.05 -0.02 (-1.87%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends OKYO vs. DRUG, PBYI, IVA, ABOS, SGMT, BDTX, CADL, TELO, CGEN, and SKYEShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Bright Minds Biosciences (DRUG), Puma Biotechnology (PBYI), Inventiva (IVA), Acumen Pharmaceuticals (ABOS), Sagimet Biosciences (SGMT), Black Diamond Therapeutics (BDTX), Candel Therapeutics (CADL), Telomir Pharmaceuticals (TELO), Compugen (CGEN), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Bright Minds Biosciences Puma Biotechnology Inventiva Acumen Pharmaceuticals Sagimet Biosciences Black Diamond Therapeutics Candel Therapeutics Telomir Pharmaceuticals Compugen Skye Bioscience OKYO Pharma (NASDAQ:OKYO) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings. Which has preferable valuation and earnings, OKYO or DRUG? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$16.83MN/AN/ABright Minds BiosciencesN/AN/A-$5.47M-$0.68-51.96 Which has more risk and volatility, OKYO or DRUG? OKYO Pharma has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.62, meaning that its stock price is 762% less volatile than the S&P 500. Is OKYO or DRUG more profitable? OKYO Pharma's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A Bright Minds Biosciences N/A -58.55%-53.79% Do analysts rate OKYO or DRUG? OKYO Pharma currently has a consensus price target of $7.00, suggesting a potential upside of 566.67%. Given OKYO Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe OKYO Pharma is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor OKYO or DRUG? In the previous week, Bright Minds Biosciences had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Bright Minds Biosciences and 0 mentions for OKYO Pharma. Bright Minds Biosciences' average media sentiment score of 0.21 beat OKYO Pharma's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Overall Sentiment OKYO Pharma Neutral Bright Minds Biosciences Neutral Do insiders and institutionals hold more shares of OKYO or DRUG? 3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer OKYO or DRUG? OKYO Pharma received 8 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. CompanyUnderperformOutperformOKYO PharmaOutperform Votes8100.00% Underperform VotesNo VotesBright Minds BiosciencesN/AN/A SummaryOKYO Pharma beats Bright Minds Biosciences on 7 of the 12 factors compared between the two stocks. Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.53M$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.13%4.09%P/E RatioN/A44.06102.4617.58Price / SalesN/A392.921,234.85158.43Price / CashN/A169.3840.4736.33Price / Book-5.254.597.096.50Net Income-$16.83M-$41.63M$119.65M$226.22M7 Day Performance-1.41%2.61%2.06%3.76%1 Month Performance-14.63%-2.47%-2.46%4.63%1 Year Performance-38.24%28.24%33.95%29.20% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma2.1584 of 5 stars$1.05-1.9%$7.00+566.7%-38.2%$35.53MN/A0.007DRUGBright Minds Biosciences1.3756 of 5 stars$32.53-0.4%N/A+2,434.4%$144.11MN/A-47.62N/ANews CoverageGap DownPBYIPuma Biotechnology4.2445 of 5 stars$2.91+2.5%$7.00+140.5%-27.5%$142.85M$235.60M6.04185Analyst ForecastIVAInventiva3.0477 of 5 stars$2.66-2.9%$14.00+426.3%-34.4%$139.60M$18.91M0.00100Analyst ForecastNews CoverageGap DownABOSAcumen Pharmaceuticals2.6819 of 5 stars$2.31-2.5%$9.00+290.5%+0.4%$138.48MN/A-1.6751SGMTSagimet Biosciences2.1731 of 5 stars$4.50-0.4%$21.60+380.0%+29.3%$138.02M$2M0.008BDTXBlack Diamond Therapeutics2.827 of 5 stars$2.43flat$15.50+537.9%+8.5%$137.49MN/A-1.7790Positive NewsCADLCandel Therapeutics2.3849 of 5 stars$4.14+3.8%$11.00+166.0%+460.0%$134.31M$120,000.00-2.3960Analyst RevisionTELOTelomir PharmaceuticalsN/A$4.47+6.4%N/AN/A$132.36MN/A0.001News CoverageGap UpHigh Trading VolumeCGENCompugen3.1926 of 5 stars$1.45+1.4%$4.00+175.9%+117.4%$129.40M$33.46M72.5068Positive NewsSKYESkye Bioscience1.2641 of 5 stars$4.26-0.7%$18.67+338.7%+171.1%$129.10MN/A0.0011Insider Trade Related Companies and Tools Related Companies DRUG Alternatives PBYI Alternatives IVA Alternatives ABOS Alternatives SGMT Alternatives BDTX Alternatives CADL Alternatives TELO Alternatives CGEN Alternatives SKYE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OKYO) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
